Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nadine Herzog"'
Autor:
Maria Waltmann, Nadine Herzog, Andrea M.F. Reiter, Arno Villringer, Annette Horstmann, Lorenz Deserno
Publikováno v:
Developmental Cognitive Neuroscience, Vol 60, Iss , Pp 101226- (2023)
Precisely charting the maturation of core neurocognitive functions such as reinforcement learning (RL) and flexible adaptation to changing action-outcome contingencies is key for developmental neuroscience and adjacent fields like developmental psych
Externí odkaz:
https://doaj.org/article/345da665758544019ce87c41c3a183e1
Autor:
Nadine Herzog, Maria Waltmann, Hendrik Hartmann, Kathleen Wiencke, Annette Horstmann, Maria Poessel, Franziska Rausch, Lieneke Janssen, Nora Breuer
Publikováno v:
Current Addiction Reports
Animal and human studies suggest that diet-induced obesity and plasticity in the central dopaminergic system are linked. However, it is unclear whether observed changes depend on diet or obesity, and whether they are specific to brain regions and cog
Autor:
Lieneke Janssen, Nora Breuer, Hendrik Hartmann, Maria Waltmann, Kathleen Wiencke, Maria Poessel, Annette Horstmann, Nadine Herzog, Franziska Rausch
Publikováno v:
Current Addiction Reports. 6:558-558
The original article unfortunately contained a mistake. In the online version of the paper, the entire Box 1 is missing, and the labels of the 2 tables are swapped. The original version has been corrected.
Autor:
Nadine Herzog, Job van der Palen, Karel A. Kroeze, Lonneke I. M. Lenferink, Muirne C. S. Paap
Publikováno v:
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, 14. BioMed Central
HEALTH AND QUALITY OF LIFE OUTCOMES, 14(1):97. BMC
Health and quality of life outcomes, 14:97. BioMed Central
Health and Quality of Life Outcomes, 14. BioMed Central
HEALTH AND QUALITY OF LIFE OUTCOMES, 14(1):97. BMC
Health and quality of life outcomes, 14:97. BioMed Central
Background Health-related quality of life (HRQoL) is widely used as an outcome measure in the evaluation of treatment interventions in patients with chronic obstructive pulmonary disease (COPD). In order to address challenges associated with existing
Autor:
Friedhelm R. Schuster, Michael Dworzak, Andreas H. Groll, Hans-Jürgen Laws, Andishe Attarbaschi, Nadine Herzog, Thomas Lehrnbecher, Lorenz Grigull, Karin Beutel
Publikováno v:
The Journal of antimicrobial chemotherapy. 57(3)
Although a paediatric dosage has not been established, caspofungin is occasionally used in paediatric patients. We conducted a multicentre retrospective survey to obtain data on immunocompromised paediatric patients considered to require caspofungin
Autor:
Karin Beutel, Andreas H. Groll, Michael Dworzak, Thomas Lehrnbecher, Nadine Herzog, Andishe Attarbaschi, Lorenz Grigull, Hans-Jürgen Laws, Friedhelm R. Schuster
Publikováno v:
Blood. 104:5066-5066
Background : Caspofungin (CAS) is a novel echinocandin, which is approved for several antifungal indications in adults. Although the compound is not licensed in pediatric patients (pts), it is being used in children with refractory infections or into
Autor:
Andreas H. Groll, Andishe Attarbaschi, Friedhelm R. Schuster, Nadine Herzog, Lorenz Grigull, Michael N. Dworzak, Karin Beutel, Hans-Jürgen Laws, Thomas Lehrnbecher
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Mar2006, Vol. 57 Issue 3, p527-535, 9p